Amgen Inc (AMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Summary

Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc (AMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

2
List of Tables 9
List of Figures 12
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16
Amgen Inc, Medical Devices Deals, 2011 to YTD 2017 18
Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Amgen Inc, Pharmaceuticals & Healthcare, Deal Details 26
Asset Purchase 26
Amgen Acquired Right to BI 836909 from Boehringer Ingelheim 26
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD479 Million 26
Amgen Completes Acquisition Of Dublin Sterile Plant From Pfizer 28
Amgen Reacquires Rights Of Its Products From Hypermarcas 29
Venture Financing 30
SiteOne Therapeutics Raises USD15 Million in Series B Financing 30
Dezima Pharma Raises US$13 Million In Series A Financing 31
Dezima Pharma Raises Funds Through Seed Financing 32
Gamida Cell Raises US$10 Million In Series E Financing 33
Partnerships 35
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 35
Amgen and Array BioPharma Enter into Agreement 36
Elasmogen, Feldan Bio Enter into Agreement with Amgen 36
SiteOne Therapeutics Enters into R&D Agreement with Amgen 37
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 38
Nuevolution Enters into Research Agreement with Amgen 39
Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 39
Dr. Reddys Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 40
Amgen Enters into Partnership with Advaxis 41
Amgen Enters into Agreement with Allergan 42
Amgen and Daiichi Sankyo Enter into Agreement 43
Flatiron Health Partners with Amgen 43
Amgen and Merck Enter into Agreement 44
Amgen Expands its Co-Development Agreement with Novartis 45
Dr. Reddys Labs Enters into Distribution Agreement with Amgen 46
Amgen Enters into Research Agreement with MD Anderson 47
Innovative Targeting Solutions Enters into Research Agreement with Amgen 48
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 48
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 49
Amgen Forms Joint Venture With Zhejiang Beta Pharma 50
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 52
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 53
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 54
Amgen Enters Into Co-Development Agreement With Astellas 55
Amgen And Astellas Pharma Announce Joint Venture For Japan 56
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 57
PeptiDream Expands Drug Discovery Agreement with Amgen 58
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 58
Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 59
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 60
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 61
Dako Enters Into Co-Development Agreement With Amgen 62
Dako Enters Into Co-Development Agreement With Amgen 63
Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs 64
Multiple Myeloma Research Enters Into Co-Development Agreement With Onyx Pharma 66
deCODE genetics Enters Into Research Agreement With Pfizer 66
Micromet Enters Into Research Agreement With Amgen For BiTE Antibodies 67
S*Bio Amends Collaboration With Onyx Pharma 68
Merger 69
AstraZeneca Rumored To Merge With Amgen 69
Licensing Agreements 70
Amgen Enters into Licensing Agreement with Ligand Pharma 70
Amgen Enters into Licensing Agreement with Immatics Biotech 70
Amgen Enters into Licensing Agreement with Teijin Pharma 71
Amgen Enters into Licensing Agreement with Xencor 72
FLX Bio Enters Into Licensing Agreement with Amgen 73
Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 74
Amgen Enters into Licensing Agreement with Kite Pharma 74
Cancer Research UK Enters into Licensing Agreement with Amgen 76
Remd Biotherapeutics Enters into Licensing Agreement with Amgen 77
Atara Biotherapeutics Enters Into Licensing Agreement with Amgen 77
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 77
Amgen Enters into Licensing Agreement with Arrowhead Pharma 79
Roche Enters into Licensing Agreement with Amgen 80
NantPharma Enters into Licensing Agreement with Amgen for AMG 337 80
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 81
Open Monoclonal Enters into Licensing Agreement with Amgen 82
Celimmune Enters into Licensing Agreement with Amgen for AMG 714 82
NantWorks Enters into Licensing Agreement with Amgen for AMG 479 83
Amgen Expands its Licensing Agreement with Carmot Therapeutics 84
Amgen Enters Into Licensing Agreement With R-Pharm 85
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 86
Cytokinetics Expands Licensing Agreement With Amgen For Omecamtiv Mecarbil 87
Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 88
Selexis Expands License Agreement With Amgen 89
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 90
DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 91
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 91
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 93
Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169 94
Tesaro Enters Into Licensing Agreement With Amgen 95
MedImmune Enters Into Licensing Agreement With Amgen For AMG 108 95
Equity Offering 96
Arrowhead Pharma to Raise Funds through Public Offering of Shares 96
Onyx Pharma Completes Public Offering Of Common Stock For US$358.6 Million 98
Debt Offering 99
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 99
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 100
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 102
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 103
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 104
Amgen Completes Public Offering Of Notes Due 2018 For US$736 Million 106
Amgen Completes Public Offering Of 5.50% Notes Due 2026 For US$740 Million 107
Amgen Completes Public Offering Of 5.15% Senior Notes Due 2041 For US$2.25 Billion 108
Amgen Completes Public Offering Of 3.875% Senior Notes Due 2021 For US$1.75 Billion 110
Amgen Completes Public Offering Of 1.875% Senior Notes Due 2014 For US$1 Billion 111
Amgen Completes Public Offering Of 2.5% Senior Notes Due 2016 For US$1 Billion 112
Amgen Completes Public Offering Of 4.10% Senior Unsecured Notes Due 2021 For US$1,000 Million 113
Amgen Completes Public Offering Of 2.30% Senior Unsecured Notes Due 2016 For US$750 Million 114
Amgen Completes Public Offering Of 5.65% Senior Unsecured Notes Due 2042 For US$1,250 Million 115
Asset Transactions 116
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 116
Boehringer Ingelheim Acquires Fremont Facility From Amgen 117
Acquisition 118
Amgen to Acquire Catherex from Medigene 118
Amgen Acquires Dezima Pharma 119
Amgen Completes Acquisition of Onyx Pharma For Up To US$10.4 Billion in Tender Offer 120
Biocad Rumored To Sell Itself For Up To US$1 Billion 122
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million 123
Amgen Completes Acquisition Of KAI Pharma For US$315 Million 125
Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For US$700 Million 126
Amgen Completes Acquisition Of Micromet For US$1.16 Billion 128
Amgen Acquires Bergamo 130
Amgen Completes The Acquisition Of BioVex For US$1 Billion 130
Amgen Inc - Key Competitors 134
Key Employees 135
Locations And Subsidiaries 137
Head Office 137
Other Locations & Subsidiaries 137
Recent Developments 144
Strategy And Business Planning 144
Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 144
Financial Announcements 145
Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 145
Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 148
Oct 27, 2016: Amgen Reports Third Quarter 2016 Financial Results 151
Jul 27, 2016: Amgen Reports Second Quarter 2016 Financial Results 154
Apr 28, 2016: Amgens First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90 157
Jan 28, 2016: Amgens 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share Increased 19 Percent To $10.38 159
Corporate Communications 161
Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 161
Oct 14, 2016: Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors 162
Legal and Regulatory 163
Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 163
Jul 20, 2016: Amgen Announces Settlement Of Securities Litigation 164
Government and Public Interest 165
Sep 26, 2016: Amgen Opens Nomination Process For LabCentral Residency 165
May 18, 2016: Landmark deCODE genetics Study Points to a New Mechanism that Affects Cholesterol Levels and The Risk of Heart Disease 166
May 05, 2016: NICE draft guidance recommends new drugs for cholesterol disorder 167
Product News 168
Dec 12, 2016: Discussion on Advaxis ADXS-NEO Program Held During the International Congress on Immunotherapies in Cancer 168
Nov 07, 2016: Amgen To Present Data On ABP 710 At ACR/ARHP 2016 Annual Meeting 169
Nov 07, 2016: Amgen To Present Data On Denosumab At ACR/ARHP 2016 Annual Meeting 170
Nov 07, 2016: Amgen To Present Data On Etanercept At ACR/ARHP 2016 Annual Meeting 171
Nov 07, 2016: Amgen To Present Data Romosozumab At ACR/ARHP 2016 Annual Meeting 172
Nov 04, 2016: FDA Approves Expanded Use Of ENBREL (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis 173
Oct 10, 2016: New Retrospective Analyses Confirm Vectibix (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin 174
Oct 06, 2016: Talimogene laherparepvec in melanoma: Added benefit not proven 176
Oct 03, 2016: Study Results Published In Journal of Clinical Oncology Show BLINCYTO (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia 177
Sep 07, 2016: ONO Launches KYPROLIS for Intravenous Injection 10 mg and 40 mg Proteasome Inhibitor 179
Sep 07, 2016: Amgen to Highlight Abstracts on Prolia (denosumab) at American Society for Bone and Mineral Research Annual Meeting 180
Sep 01, 2016: FDA Approves BLINCYTO (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia 182
Jul 11, 2017: FDA Grants Full Approval for BLINCYTO (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children 183
Jul 04, 2016: ONO Receives Manufacturing and Marketing Approval in Japan for KYPROLIS, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma 185
Jun 23, 2017: European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia 186
Jun 09, 2016: Preliminary data for pre-kidney transplant being presented June 13 187
Jun 03, 2016: Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers 188
May 27, 2016: Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 189
May 26, 2016: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" 190
May 19, 2016: Amgen Highlights Data on BLINCYTO at 21st Congress Of The European Hematology Association 191
May 19, 2016: Amgen Highlights Data on Kyprolis at 21st Congress Of The European Hematology Association 192
Apr 19, 2016: AACR Research Reception Highlights ADXS-NEO at the American Association for Cancer Research Annual Meeting 194
Mar 29, 2017: FDA Grants Priority Review For Amgens BLINCYTO (blinatumomab) Supplemental Biologics License Application 195
Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-NEO at AACR Abstract 197
Mar 06, 2017: Amgen to Present New Data on Omecamtiv Mecarbil at the American College of Cardiology 66th Annual Scientific Session 198
Feb 12, 2016: New Drug Treatment Kyprolis (carfilzomib) for Relapsed Multiple Myeloma Launches in the UK 199
Feb 05, 2016: Single-lesion biopsy may be insufficient to choose therapy targeting resistance mutations 201
Jan 16, 2017: The Scottish Medicines Consortium declines two life-prolonging myeloma treatments 203
Product Approvals 204
Mar 06, 2017: Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO 204
Feb 14, 2017: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 205
Jan 27, 2017: Withdrawal of the application for a change to the marketing authorisation for Xgeva (denosumab) 207
Dec 19, 2016: Amgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan 208
Dec 02, 2016: Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab 210
Nov 15, 2016: Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration 211
Sep 30, 2016: Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma 212
Sep 26, 2016: Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab 213
Sep 23, 2016: Daiichi Sankyo Announces Application in Japan for Additional Indication for Anti-RANKL Antibody, Denosumab 214
Sep 07, 2016: ONO Submits Supplemental New Drug Application in Japan for KYPROLIS for Intravenous Injection 10 mg and 40 mg, a Proteasome Inhibitor, for Relapsed or Refractory Multiple Myeloma 215
Jul 21, 2016: Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA 216
Jul 03, 2016: European Commission Approves Extended Indication For Amgens Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients 217
May 03, 2016: FDA Grants Priority Review For Amgens Supplemental Biologics License Application For BLINCYTO (Blinatumoma) 219
Mar 16, 2016: NICE consults on no recommendation for skin cancer drug talimogene laherparepvec 221
Mar 10, 2016: FDA Accepts Amgen Supplemental Biologics License Application For The Expanded Use Of Enbrel (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis 222
Mar 01, 2016: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) 223
Jan 26, 2016: NICE issues final guidance recommending etanercept for rheumatoid arthritis 224
Jan 21, 2016: FDA Approves New Kyprolis (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma 225
Jan 12, 2016: Health Canada approves Amgens BLINCYTO (blinatumomab) for the treatment of relapsed or refractory B-cell precursor Acute lymphoblastic leukemia 227
Clinical Trials 228
Jun 21, 2017: Amgen To Present Data on BLINCYTO At 22nd Congress of the European Hematology Association 228
Jun 02, 2017: City of Hope Presents Study Results of Blinatumomab at 2017 American Society of Clinical Oncology meeting 229
Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) 230
Mar 29, 2017: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia 231
Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 233
Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 234
Mar 01, 2017: BLINCYTO (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy 236
Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 238
Dec 01, 2016: Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil 239
Nov 30, 2016: Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia At ASH 2016 240
Nov 30, 2016: Amgen Announces Presentation Of New Data In Multiple Myeloma At ASH 2016 241
Nov 30, 2016: The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure 242
Nov 16, 2016: Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study 244
Nov 14, 2016: Arrowhead Pharmaceuticals Presents New Data on ARC-LPA Using DPCsq Subcutaneous RNAi Delivery Vehicle 245
Nov 14, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the AHA Annual Scientific Meeting 246
Nov 12, 2016: Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis 247
Nov 11, 2016: UCB Presents Data on romosozumab at 2016 ACR/ARHP Annual Meeting 249
Nov 07, 2016: Cytokinetics Announces New Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2016 250
Oct 20, 2016: Amgen Announces Positive Top-Line Results From XGEVA (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients 251
Oct 05, 2016: Amgen Presents Data on Vectibix (Panitumumab) At The European Society For Medical Oncology 2016 Congress 252
Oct 05, 2016: Amgen To Present Data On IMLYGIC (talimogene laherparepvec) At The European Society For Medical Oncology 2016 Congress 253
Sep 28, 2016: Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study 254
Sep 27, 2016: Amgen Announces Top-Line Results From Phase 3 KYPROLIS (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients 255
Sep 19, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting 256
Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis 257
Sep 15, 2016: Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine 259
Sep 15, 2016: Novartis announces new positive data showing AMG 334 significantly reduces monthly migraine days in chronic migraine vs placebo 261
Sep 14, 2016: Amgen present erenumab at webcast call 263
Sep 14, 2016: Amgen to present romosozumab at Investor Call 264
Sep 09, 2016: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting 265
Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting 266
Sep 01, 2016: Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development 268
Aug 29, 2016: Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia (Denosumab) In Patients Receiving Glucocorticoid Therapy 269
Jul 21, 2016: Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer 270
Jun 10, 2016: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 272
Jun 10, 2016: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression 273
Jun 08, 2016: Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine 277
Jun 08, 2016: UCB presents Phase 3 data from the STRUCTURE study of Romosozumab at the Annual European Congress of Rheumatology (EULAR 2016) 278
Jun 06, 2016: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen 279
May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress 281
May 18, 2016: Amgen To Present Data on IMLYGIC (talimogene laherparepvec) At ASCO 2016 282
May 18, 2016: Amgen To Present Data on Kyprolis (carfilzomib) At ASCO 2016 283
May 18, 2016: Amgen To Present Data on Vectibix (panitumumab) At ASCO 2016 284
May 18, 2016: Amgen To Presented Data on ABP 215 At ASCO 2016 285
May 13, 2016: Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 2016 286
May 06, 2016: Arrowhead Pharmaceuticals Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration 287
Apr 04, 2016: Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure 288
Apr 01, 2016: Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide 289
Mar 30, 2016: Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment 291
Mar 20, 2016: Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis 292
Mar 04, 2016: Southampton experts trial new drug to help immune system fight cancer 293
Feb 24, 2016: Cancer Research UK launches trial for potential new drug that could help immune system fight cancer 294
Feb 21, 2016: Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis 295
Feb 10, 2016: Finding the best treatment for bowel cancer patients 297
Feb 04, 2016: Phase 3 Study of BLINCYTO (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 298
Jan 23, 2016: Vectibix (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer 299
Other Significant Developments 301
Sep 06, 2016: Syngene International Commissions Dedicated R&D Center for Amgen 301
Appendix 302
Methodology 302
About GlobalData 302
Contact Us 302
Disclaimer 302

List Of Tables


Amgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Amgen Inc, Deals By Therapy Area, 2011 to YTD 2017 16
Amgen Inc, Medical Devices Deals, 2011 to YTD 2017 18
Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Amgen Acquired Right to BI 836909 from Boehringer Ingelheim 26
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD479 Million 26
Amgen Completes Acquisition Of Dublin Sterile Plant From Pfizer 28
Amgen Reacquires Rights Of Its Products From Hypermarcas 29
SiteOne Therapeutics Raises USD15 Million in Series B Financing 30
Dezima Pharma Raises US$13 Million In Series A Financing 31
Dezima Pharma Raises Funds Through Seed Financing 32
Gamida Cell Raises US$10 Million In Series E Financing 33
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 35
Amgen and Array BioPharma Enter into Agreement 36
Elasmogen, Feldan Bio Enter into Agreement with Amgen 36
SiteOne Therapeutics Enters into R&D Agreement with Amgen 37
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 38
Nuevolution Enters into Research Agreement with Amgen 39
Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 39
Dr. Reddys Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 40
Amgen Enters into Partnership with Advaxis 41
Amgen Enters into Agreement with Allergan 42
Amgen and Daiichi Sankyo Enter into Agreement 43
Flatiron Health Partners with Amgen 43
Amgen and Merck Enter into Agreement 44
Amgen Expands its Co-Development Agreement with Novartis 45
Dr. Reddys Labs Enters into Distribution Agreement with Amgen 46
Amgen Enters into Research Agreement with MD Anderson 47
Innovative Targeting Solutions Enters into Research Agreement with Amgen 48
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 48
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 49
Amgen Forms Joint Venture With Zhejiang Beta Pharma 50
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 52
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 53
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 54
Amgen Enters Into Co-Development Agreement With Astellas 55
Amgen And Astellas Pharma Announce Joint Venture For Japan 56
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 57
PeptiDream Expands Drug Discovery Agreement with Amgen 58
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 58
Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 59
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 60
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 61
Dako Enters Into Co-Development Agreement With Amgen 62
Dako Enters Into Co-Development Agreement With Amgen 63
Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs 64
Multiple Myeloma Research Enters Into Co-Development Agreement With Onyx Pharma 66
deCODE genetics Enters Into Research Agreement With Pfizer 66
Micromet Enters Into Research Agreement With Amgen For BiTE Antibodies 67
S*Bio Amends Collaboration With Onyx Pharma 68
AstraZeneca Rumored To Merge With Amgen 69
Amgen Enters into Licensing Agreement with Ligand Pharma 70
Amgen Enters into Licensing Agreement with Immatics Biotech 70
Amgen Enters into Licensing Agreement with Teijin Pharma 71
Amgen Enters into Licensing Agreement with Xencor 72
FLX Bio Enters Into Licensing Agreement with Amgen 73
Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 74
Amgen Enters into Licensing Agreement with Kite Pharma 74
Cancer Research UK Enters into Licensing Agreement with Amgen 76
Remd Biotherapeutics Enters into Licensing Agreement with Amgen 77
Atara Biotherapeutics Enters Into Licensing Agreement with Amgen 77
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 77
Amgen Enters into Licensing Agreement with Arrowhead Pharma 79
Roche Enters into Licensing Agreement with Amgen 80
NantPharma Enters into Licensing Agreement with Amgen for AMG 337 80
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 81
Open Monoclonal Enters into Licensing Agreement with Amgen 82
Celimmune Enters into Licensing Agreement with Amgen for AMG 714 82
NantWorks Enters into Licensing Agreement with Amgen for AMG 479 83
Amgen Expands its Licensing Agreement with Carmot Therapeutics 84
Amgen Enters Into Licensing Agreement With R-Pharm 85
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 86
Cytokinetics Expands Licensing Agreement With Amgen For Omecamtiv Mecarbil 87
Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 88
Selexis Expands License Agreement With Amgen 89
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 90
DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 91
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 91
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 93
Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169 94
Tesaro Enters Into Licensing Agreement With Amgen 95
MedImmune Enters Into Licensing Agreement With Amgen For AMG 108 95
Arrowhead Pharma to Raise Funds through Public Offering of Shares 96
Onyx Pharma Completes Public Offering Of Common Stock For US$358.6 Million 98
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 99
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 100
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 102
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 103
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 104
Amgen Completes Public Offering Of Notes Due 2018 For US$736 Million 106
Amgen Completes Public Offering Of 5.50% Notes Due 2026 For US$740 Million 107
Amgen Completes Public Offering Of 5.15% Senior Notes Due 2041 For US$2.25 Billion 108
Amgen Completes Public Offering Of 3.875% Senior Notes Due 2021 For US$1.75 Billion 110
Amgen Completes Public Offering Of 1.875% Senior Notes Due 2014 For US$1 Billion 111
Amgen Completes Public Offering Of 2.5% Senior Notes Due 2016 For US$1 Billion 112
Amgen Completes Public Offering Of 4.10% Senior Unsecured Notes Due 2021 For US$1,000 Million 113
Amgen Completes Public Offering Of 2.30% Senior Unsecured Notes Due 2016 For US$750 Million 114
Amgen Completes Public Offering Of 5.65% Senior Unsecured Notes Due 2042 For US$1,250 Million 115
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 116
Boehringer Ingelheim Acquires Fremont Facility From Amgen 117
Amgen to Acquire Catherex from Medigene 118
Amgen Acquires Dezima Pharma 119
Amgen Completes Acquisition of Onyx Pharma For Up To US$10.4 Billion in Tender Offer 120
Biocad Rumored To Sell Itself For Up To US$1 Billion 122
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For US$401 Million 123
Amgen Completes Acquisition Of KAI Pharma For US$315 Million 125
Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For US$700 Million 126
Amgen Completes Acquisition Of Micromet For US$1.16 Billion 128
Amgen Acquires Bergamo 130
Amgen Completes The Acquisition Of BioVex For US$1 Billion 130
Amgen Inc, Key Competitors 134
Amgen Inc, Key Employees 135
Amgen Inc, Other Locations 137
Amgen Inc, Subsidiaries 139

List Of Figures


Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 14
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16
Amgen Inc, Medical Devices Deals, 2011 to YTD 2017 18

Amgen Full Year Operating Financial

Amgen 2023 Full Year Operating and Financial Review--SWOT Analysis, Technological Know-How, M&A, Senior Management, Goals and Strategies in the Global Pharmaceutical Industry This report is part of the Competitive

USD 750 View Report

Amgen 2023 Third Quarter Operating and Financial Review

Amgen 2023 Third Quarter Operating and Financial Review--SWOT Analysis, Technological Know-How, M&A, Senior Management, Goals and Strategies in the Global Pharmaceutical Industry This report is part of the Competitive

USD 750 View Report

Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review

Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available